Regeneron Pharmaceuticals, Inc. insider Arthur F. Ryan reported a sale of Regeneron common stock on July 2, 2026. The Form 4, signed by Ryan on July 7, 2026, discloses that he sold 200 shares of REGN common stock in a transaction coded as a sale/disposition. The shares were sold under a trading plan intended to comply with Rule 10b5-1(c), which Ryan adopted on October 31, 2025. Such plans allow insiders to schedule trades in advance, helping reduce concerns that transactions are based on material nonpublic information. The filing states that the 200 shares were sold at a volume-weighted average price, with individual sale prices ranging from $650.10 to $650.19 per share. Based on that range, the transaction was worth approximately $130,000 in gross proceeds before commissions or taxes. The filing notes that Ryan will provide full price-by-price details to the SEC staff, the company, or a Regeneron security holder upon request. No option exercise, restricted stock vesting, or other derivative-security transaction was reported in the provided document. The excerpt also does not state Ryan’s beneficial ownership after the sale. The key reported action is therefore a small planned insider sale of Regeneron common stock under a prearranged 10b5-1 trading plan.